Search

everythinglearnresearchcommunity

for

Search:↓

The post is about the potential legal trouble of bringing a four-month supply of fluridil, a hair loss treatment, into non-Western countries.

A 26-year-old male is documenting his hair regrowth journey using 0.5mg dutasteride and 5mg oral minoxidil, transitioning from 5% topical minoxidil. He reports no significant side effects after one week, except for slight water retention and increased libido.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

A user shared their positive experience with a hair transplant in Turkey, using 4350 grafts, and described it as the best decision of their life. They discussed using finasteride to maintain non-transplanted hair and addressed questions about the procedure and recovery.

A 25-year-old male experienced hair regrowth after switching from topical minoxidil to a combination of topical minoxidil and oral finasteride, along with microneedling and multivitamins. He reported no significant side effects from finasteride, except mild discomfort, and emphasized the effectiveness of oral finasteride over topical solutions.

A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

A user shared progress pictures after 5.5 months of using finasteride, minoxidil foam, vitamin D3, and ketoconazole shampoo for hair loss but hasn't seen progress yet. They are advised to wait a year before considering additional treatments like dutasteride.

The user is considering reducing their finasteride dose from 2.5mg to 1.25mg to make the supply last longer and is concerned about potential changes in results. They have been using the 2.5mg dose for four months.

The user is considering switching from a stamp to a pen for hair treatment due to poor results with the stamp. They are concerned about the availability of pen refills and are seeking better outcomes with the pen.

A user shared their 5-month progress using a topical treatment with finasteride, minoxidil, and retinoic acid, noting some hair growth but also shedding. Another user encouraged them, sharing their own experience of gradual improvement over 12 months and advising patience.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.

The user "LandB4TimeIn3D" shared their hair loss progress using finasteride (Fin) and minoxidil (Min). They experienced shedding for the first few years but saw significant regrowth after about 2-3 years. They also mentioned using topical liquid minoxidil twice a day.

The user has been using finasteride and minoxidil for over a year and is seeing thin hair regrowth with some 1cm hairs still growing. They are considering a hair transplant and are taking zinc to manage side effects.

User experienced shortness of breath, high blood pressure, red eyes, and eye floaters after using RU58841 for hair loss. They warn others to avoid RU58841 and stick to finasteride, minoxidil, and dutasteride.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

Making a hair solution using RU58841 from raw powder. Users humorously compare the process to a science experiment.

The user is experiencing hair thinning and shedding despite no family history of male pattern baldness. They are considering starting treatments like Minoxidil or finasteride.

A 28-year-old male started a hair loss treatment with 2.5mg oral minoxidil daily, 1mg finasteride every other day, and a 1.5mm dermaroller once a week. After two months, he believes he sees some progress.

The user noticed slight hair loss after switching to Milpharm finasteride and is considering switching to Accord finasteride. They seek advice on whether to continue with Milpharm or switch brands.

The user experienced significant hair improvement using 1mg finasteride and 2.5mg oral minoxidil daily, with most gains attributed to finasteride. They also stopped using topical treatments due to scalp psoriasis and reported no major side effects.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

User reported initial hair regrowth with 0.25 mg finasteride taken four times a week, experiencing a second shedding phase, and no side effects. They also mentioned using RU58841 without success and plan to stop after a year.